MATTHEW TOMAN: Open Payments
NPI 1750894952 · NAPERVILLE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,862 in 87 payments from 37 companies in 2025. Trend: 2023 $137 · 2024 $61 · 2025 $1,862
Food & beverage: $1,862
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $195 |
| ABBVIE INC. | 9 | $187 |
| Janssen Biotech, Inc. | 9 | $159 |
| Celgene Corporation | 7 | $135 |
| Incyte Corporation | 4 | $87 |
| PUMA BIOTECHNOLOGY, INC. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Karyopharm Therapeutics Inc. | 2 | $66 |
| Lilly USA, LLC | 3 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $56 |
Products named: REBLOZYL, KISQALI, VENCLEXTA, TALVEY, NERLYNX, XPOVIO, VERZENIO, JAKAFI.
Industry payments across IL — which companies pay providers there.
